ETOFIBRATE

Etofibrate is a lipid-modifying agent combining fenofibric acid and niacin activity to reduce triglycerides and cholesterol. Side effects include flushing, GI upset, and muscle pain.

SKU: 3fc8da803e9c Category: Tag:

Product Description


Mechanism of Action

Etofibrate is a prodrug conjugate of clofibrate and theophylline. After enzymatic hydrolysis, it releases clofibric acid (a PPAR‑α activator that enhances lipid metabolism) and theophylline (a xanthine bronchodilator). This dual‑action profile influences lipid homeostasis and respiratory smooth‑muscle function.

Benefits and Advantages

Used in lipid‑metabolism modelling, PPAR‑α activation assays, dual‑prodrug studies, and xanthine‑bronchodilator pharmacology.

Side Effects and Risks

Risks include GI discomfort, hepatotoxicity, tachycardia (from theophylline), and photosensitivity. Handle with fibrate‑xanthine combination precautions.

Datasheet


Molecular Formula

C20H26O6

Molecular Weight

363.8 g/mol

CAS Number

31637-97-5

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Etofibrate; 31637-97-5; Etofibrato; Etofibratum; DTXSID80185521

IUPAC/Chemical Name

2-[2-(4-chlorophenoxy)-2-methylpropanoyl]oxyethyl pyridine-3-carboxylate

InChl Key

XXRVYAFBUDSLJX-UHFFFAOYSA-N

InChl Code

InChI=1S/C18H18ClNO5/c1-18(2,25-15-7-5-14(19)6-8-15)17(22)24-11-10-23-16(21)13-4-3-9-20-12-13/h3-9,12H,10-11H2,1-2H3

References

https://pubchem.ncbi.nlm.nih.gov/compound/65777;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download